PPH 📈 VanEck Pharmaceutical - Overview
Exchange: NASDAQ • Country: USA • Currency: USD • Type: Etf • ISIN: US92189F6925 • Health
PPH: Pharmaceuticals, Medicines, Biotechnology, Vaccines, Therapies, Treatments
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified. ‣ Company URL: http://www.vaneck.com ‣ Domicile: United States
Additional Sources for PPH ETF
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
PPH ETF Overview
| Market Cap in USD | 595m |
| Category | Health |
| TER | 0.36% |
| IPO / Inception | 2011-12-20 |
PPH ETF Ratings
| Growth 5y | 64.4% |
| Fundamental | - |
| Dividend | 46.2% |
| Rel. Strength Industry | -84.6 |
| Analysts | - |
| Fair Price Momentum | 81.38 USD |
| Fair Price DCF | - |
PPH Dividends
| Dividend Yield 12m | 1.49% |
| Yield on Cost 5y | 2.22% |
| Annual Growth 5y | 3.29% |
| Payout Consistency | 87.5% |
PPH Growth Ratios
| Growth Correlation 3m | -85.4% |
| Growth Correlation 12m | 49.2% |
| Growth Correlation 5y | 95% |
| CAGR 5y | 8.27% |
| CAGR/Mean DD 5y | 1.61 |
| Sharpe Ratio 12m | 0.03 |
| Alpha | -14.78 |
| Beta | 0.69 |
| Volatility | 13.52% |
| Current Volume | 124.8k |
| Average Volume 20d | 150.5k |
What is the price of PPH stocks?
As of January 08, 2025, the stock is trading at USD 87.06 with a total of 124,800 shares traded.
Over the past week, the price has changed by +0.90%, over one month by -2.79%, over three months by -6.19% and over the past year by +4.32%.
As of January 08, 2025, the stock is trading at USD 87.06 with a total of 124,800 shares traded.
Over the past week, the price has changed by +0.90%, over one month by -2.79%, over three months by -6.19% and over the past year by +4.32%.
Is VanEck Pharmaceutical a good stock to buy?
Yes. Based on ValueRay Analyses, VanEck Pharmaceutical (NASDAQ:PPH) is currently (January 2025) a good stock to buy. It has a ValueRay Growth Rating of 64.37 and therefor a clear technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PPH as of January 2025 is 81.38. This means that PPH is currently overvalued and has a potential downside of -6.52%.
Yes. Based on ValueRay Analyses, VanEck Pharmaceutical (NASDAQ:PPH) is currently (January 2025) a good stock to buy. It has a ValueRay Growth Rating of 64.37 and therefor a clear technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PPH as of January 2025 is 81.38. This means that PPH is currently overvalued and has a potential downside of -6.52%.
Is PPH a buy, sell or hold?
VanEck Pharmaceutical has no consensus analysts rating.
VanEck Pharmaceutical has no consensus analysts rating.
What are the forecast for PPH stock price target?
According to ValueRays Forecast Model, PPH VanEck Pharmaceutical will be worth about 89.6 in January 2026. The stock is currently trading at 87.06. This means that the stock has a potential upside of +2.92%.
According to ValueRays Forecast Model, PPH VanEck Pharmaceutical will be worth about 89.6 in January 2026. The stock is currently trading at 87.06. This means that the stock has a potential upside of +2.92%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 89.6 | 2.9% |